2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Abstract Full Text (PDF) All Versions of this Article: ASN.2006060601v1 17/9/2359    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marckmann, P. Articles by Thomsen, H. S. Search for Related Content PubMed PubMed Citation Articles by Marckmann, P. Articles by Thomsen, H. S.

Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging

Peter Marckmann^*, Lone Skov, Kristian Rossen, Anders Dupont, Mette Brimnes Damholt^*, James Goya Heaf^* and Henrik S. Thomsen^||

Departments of ^* Nephrology and ^|| Diagnostic Radiology, Copenhagen University Hospital at Herlev, Herlev, Departments of Dermatology and Pathology, Copenhagen University Hospital at Gentofte, Hellerup, and Faculty of Health Sciences, Copenhagen University, Copenhagen, Denmark

Address correspondence to: Dr. Peter Marckmann, Department of Nephrology, Copenhagen University Hospital at Herlev, DK-2730 Herlev, Denmark. Phone: +45-44883634; Fax: +45-44884615; E-mail: peter.marckmann{at}dadlnet.dk

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
Nephrogenic systemic fibrosis is a new, rare disease of unknown cause that affects patients with renal failure. Single cases led to the suspicion of a causative role of gadodiamide that is used for magnetic resonance imaging. This study therefore reviewed all of the authors’ confirmed cases of nephrogenic systemic fibrosis (n = 13) with respect to clinical characteristics, gadodiamide exposure, and subsequent clinical course. It was found that all had been exposed to gadodiamide before the development of nephrogenic systemic fibrosis. The delay from exposure to first sign of the disease was 2 to 75 d (median 25 d). Odds ratio for acquiring the disease when gadodiamide exposed was 32.5 (95% confidence interval 1.9 to 549.2; P < 0.0001). Seven (54%) patients became severely disabled, and one died 21 mo after exposure. No other exposure/event than gadodiamide that was common to more than a minority of the patients could be identified. These findings indicate that gadodiamide plays a causative role in nephrogenic systemic fibrosis.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
Since 1997, a total of approximately 200 cases of nephrogenic systemic fibrosis (NSF), previously known as nephrogenic fibrosing dermopathy, have been reported worldwide (1,2). The appearance of this new and serious disease has triggered considerable interest as to possible causative factors, including newly introduced clinical practices. However, until now, the eliciting factor(s) has not been identified.

Mendoza et al. (3) recently reviewed the clinical picture of NSF. The typical patient is middle-aged and has ESRD. Most but not all are on regular dialysis treatment. The typical course begins with subacute swelling of distal parts of the extremities and is followed in subsequent weeks by severe skin induration and sometimes anatomic extension to involve thighs, antebrachium, and lower abdomen. The skin induration may be aggressive and associated with constant pain, muscle restlessness, and loss of skin flexibility. In some cases, NSF leads to serious physical disability, including wheelchair requirement. NSF initially was observed in and thought to affect solely the skin (thus the initial term nephrogenic fibrosing dermopathy), but more recent patient reports have demonstrated that several organs may be involved. Organ involvement may explain the suspected increased mortality of patients with NSF (3). There is no established treatment for NSF, but some cases have been reported to improve after kidney transplantation, and others seem to have been treated successfully with extracorporeal photopheresis (4).

At the department of nephrology, Copenhagen University Hospital at Herlev, we became aware of a formerly unknown skin disease among our patients with ESRD during 2002 through 2005. Skin biopsies supported the clinical suspicion of NSF. Some of the case stories strongly indicated that the skin changes were elicited by contrast-enhanced magnetic resonance imaging (MRI). Since late 2001, we have used this method frequently for patients with ESRD, in particular for description of iliac and lower limb arteries before kidney transplantation (5). During the past 5 to 10 yr, many other nephrology centers around the world increasingly have used contrast-enhanced MRI because of the lower nephrotoxic potential of extracellular MRI agents compared with iodinated contrast media (6). On the basis of our suspicion, we decided to make a review of all NSF cases with a special focus on exposure to contrast-enhanced MRI.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
During August 2005 through May 2006, we identified all confirmed cases of NSF in our nephrology department. Each case was reviewed thoroughly with respect to clinical history and exposure to contrast-enhanced MRI. We also checked for other extraordinary exposures/events within the 6 mo before the first sign of NSF. The other exposures/events for which we checked were exposure to iodinated contrast media, scintigraphy, intravenous iron therapy, bacteremia, infection that required antibiotic therapy, thrombosis, and surgery. Patients were considered to have NSF only when the clinical course, the dermatologic findings, and the skin histology all were indicative of NSF as agreed unanimously by a panel composed of a clinician (P.M.), a dermatologist (L.S.), and a pathologist (K.R.).

Statistical Analyses
The odds ratio for developing NSF depending on gadodiamide exposure was calculated from our best estimates of the number of patients who had ESRD and had or had not been exposed. We used GraphPad Instat, version 3.05 (GraphPad Software, San Diego, CA; www.graphpad.com) for this purpose.

	Results

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
Up to June 12, 2006, we identified 13 patients (eight women, five men) with NSF. Skin histology (n = 13) varied from subtle proliferation of dermal fibroblasts consistent with NSF to frank NSF as described by Cowper et al. (7) and Swartz et al. (8).

Mean age at first sign of NSF was 50 yr (range 33 to 66 yr). All patients had ESRD, but they differed with respect to primary renal disease (Table 1). NSF proceeded to severe disability (contractures, loss of physical abilities, and deterioration of overall clinical state) in seven cases. One of the severely disabled patients (patient 4) died from cachexia and pneumonia 20 mo after the first sign of NSF. The remaining six patients were more mildly affected (leg swellings and skin induration with/without local pain). One patient had a seemingly total, spontaneous remission of a mild disease while continuing on regular hemodialysis therapy (patient 7).

Our patients with NSF belonged to different treatment categories at the time of gadodiamide exposure, including regular hemodialysis therapy (n = 7), regular peritoneal dialysis therapy (n = 1), and conservative treatment (n = 5). One patient had late failure of a renal graft (patient 1), and one patient had a recently transplanted yet poorly functioning kidney graft (patient 11).

Six of the 13 patients had been exposed to up to 25 mmol of gadodiamide earlier, apparently without developing NSF symptoms. Two patients were exposed to an additional infusion of gadodiamide after NSF had developed. The cumulative dose of gadodiamide varied from 11 to 63 mmol between patients.

Acidosis has been proposed as a causal co-factor in NSF pathogenesis (9). In our material, plasma bicarbonate was available from 12 patients (not available for patient 1) who had blood samples taken 0 to 36 d (median 14 d) before gadodiamide exposure. Mean plasma bicarbonate in these samples was 22.5 mmol/L (range 15 to 30 mmol/L; reference interval 22 to 29 mmol/L). Three patients had blood samples taken on the day of exposure. Their plasma bicarbonate levels were 18, 30, and 21 mmol/L (patients 8, 11, and 13, respectively).

From patient files of the Department of Diagnostic Radiology, we verified that a maximum of 370 of an estimated total of 800 to 1000 patients who had ESRD and attended our nephrology department during 2001 to 2006 had been exposed to gadodiamide. From a 2 x 2 contingency table (13 cases among 370 exposed, 0 cases among 430 to 630 unexposed), an odds ratio between 32.5 (95% confidence interval 1.9 to 549.2; P < 0.0001) and 47.6 (95% confidence interval 2.8 to 804.0) for having NSF when exposed was calculated.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
As described, we have seen an accumulation of the formerly unknown disease NSF among our patients with ESRD during the past 4 to 5 yr. NSF has appeared in parallel with our increased use of gadodiamide-enhanced MRI. The same parallelism is seen at the global level: The first reported NSF case was observed in 1997 (1). The first reports on the use of gadodiamide in humans appeared in 1993 (10), and the first Medline-indexed paper describing the use of gadolinium (Gd)-enhanced MRI in renal patients was published in 1997 (11).

All of our patients with NSF had been exposed to gadodiamide before their first sign of NSF. The median time from exposure to first medically recorded note of NSF was 25 d. In some cases, the delay was short and the link between exposure and NSF seemed obvious. However, in others, NSF developed less dramatically, had a more insidious course, and was diagnosed later. Importantly, we have not observed a single case of NSF among patients who were not exposed to gadodiamide. Consequently, the odds ratio for acquiring NSF when exposed is high and statistically highly significant in our material.

Our patients with NSF were younger (mean age 50 yr) compared with our average patient with ESRD (mean age 65 yr). Also, they all were in a relatively good clinical condition before the development of NSF. Most of them were potential kidney transplant candidates and had been referred for gadodiamide-based MR arteriography of iliac and lower limb vessels, which has been part of our routine pretransplantation examination program since late 2001.

In a recent case report, Grobner (9) was the first to propose that MR contrast media that contain Gd might be a trigger of NSF. He reported that five of nine hemodialysis patients who were exposed to a Gd-based contrast medium developed NSF within 2 to 4 wk. The contrast medium that was used in Grobner’s patients also was gadodiamide (Thomas Grobner, personal communication, April 2006). According to Grobner, acidosis might be an essential co-factor in the pathogenesis of NSF. Although we did not have blood samples from the day of gadodiamide exposure except in three cases, our finding of an average plasma bicarbonate of 22.5 mmol/L shortly before exposure does not support this hypothesis.

The evidence outlined above has led us to suspect gadodiamide as a causal factor in NSF. Consequently, we stopped further routine use of gadodiamide-based MRI in patients with ESRD at Copenhagen University Hospital at Herlev from March 21, 2006, until further notice. We have not seen any new NSF cases after that date.

Gadodiamide belongs to the group of extracellular contrast media that are used for MRI. It is a non–tissue-specific and nonionic low-osmolar (650 mOsm/kg) agent (12). Gadodiamide is almost exclusively excreted renally and therefore has a markedly prolonged half-life in patients with renal failure, including dialysis patients. The gadodiamide half-life of healthy volunteers is 1.3 h, of patients with end-stage renal failure is 34.3 h, of hemodialysis patients is 2.6 h, and of peritoneal dialysis patients is 52.7 h (13). It previously was considered a safe agent, even in patients with renal failure (6). The molecular structure of chelate-binding (diethylenetriaminepentaacetic acid-bis-methylamide) Gd is linear. Gadodiamide formulation differs from most other non–tissue-specific extracellular MRI agents by having an excess chelate (12 mg/ml). Whether this could have an impact on NSF development is not known. Alternatively, NSF could be a toxic reaction to free Gd that is liberated from gadodiamide. Free Gd is highly toxic, in particular in its ionic form (Gd³⁺) (14). Gadodiamide leaves two to four times more Gd in the bone than gadoteridol in patients with normal renal function (15). Because of the longer half-life of contrast Gd-based media in patients with ESRD, we speculate that Gd liberation might be causing NSF.

It is important to note that several of our patients with NSF had been exposed to gadodiamide earlier without developing signs of NSF. This observation suggests that gadodiamide was a necessary but not a sufficient cause of NSF. Certain other factors must have played a role, but we have not been able to identify any such co-factor.

	Conclusion

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
NSF is a new, rare, and serious disease that occurs primarily in middle-aged patients with ESRD. We have seen an accumulation of NSF cases in our department, which seems related to our frequent use of gadodiamide for MRI. Our review of 13 NSF cases has convinced us that we should avoid the use of gadodiamide in patients with ESRD until the suspicion of a causal link has been investigated further. We recommend that others consider the same and systematically look for signs of NSF in patients who have ESRD and were exposed previously to gadodiamide and other Gd-based contrast media.

	Footnotes

 
Published online ahead of print. Publication date available at www.jasn.org.

	References

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE: Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356 : 1000–1001, 2000[CrossRef][Medline]
2. Cowper SE, Bucala R, Leboit PE: Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: Setting the record straight. Semin Arthritis Rheum 35 : 208–210, 2006[CrossRef][Medline]
3. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA: Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35 : 238–249, 2006[CrossRef][Medline]
4. Gilliet M, Cozzio A, Burg G, Nestle FO: Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 152 : 531–536, 2005[CrossRef][Medline]
5. Perries R, Lokkegaard H, Logager V, Chabanova E, Thomsen HS: Preliminary experience with contrast-enhanced MR angiography in patients with end-stage renal failure. Acad Radiol 12 : 652–657, 2005[CrossRef][Medline]
6. Thomsen HS: Gadolinium contrast media for radiographic examinations. In: Contrast Media: SAFETY issues and ESUR Guidelines, edited by Thomsen HS, Heidelberg, Springer, 2006 , pp 115 –120
7. Cowper SE, Su LD, Bhawan J, Robin HS, Leboit PE: Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23 : 383–393, 2001[CrossRef][Medline]
8. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD: Nephrogenic fibrosing dermopathy: A novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114 : 563–572, 2003[CrossRef][Medline]
9. Grobner T: Gadolinium: A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21 : 1104–1108, 2006[Free Full Text]
10. Van Wagoner M, Worah D: Gadodiamide injection: First human experience with the nonionic magnetic resonance imaging enhancement agent. Invest Radiol 28[Suppl 1] : S44–S48, 1993[CrossRef]
11. Johnson DB, Lerner CA, Prince MR, Kazanjian SN, Narasimham DL, Leichtman AB, Cho KJ: Gadolinium-enhanced magnetic resonance angiography of renal transplants. Magn Reson Imaging 15 : 13–20, 1997[CrossRef][Medline]
12. Greenen RWF, Krestin GF: Non-tissue specific extracellular MR contrast media. In: Contrast Media: Safety Issues and ESUR Guidelines, edited by Thomsen HS, Heidelberg, Springer, 2006 , pp 107 –113
13. Joffe P, Thomsen HS, Meusel M: Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5 : 491–502, 1998[CrossRef][Medline]
14. Behra-Miellet J, Gressier B, Brunet C, Dine T, Luyckx M, Cazin M, Cazin JC: Free gadolinium and gadodiamide, a gadolinium chelate used in magnetic resonance imaging: Evaluation of their in vitro effects on human neutrophil viability. Methods Find Exp Clin Pharmacol 18 : 437–442, 1996[Medline]
15. White GW, Gibby WA, Tweedle MF: Comparison of Gd (DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 41 : 272–278, 2006[CrossRef][Medline]

This article has been cited by other articles:

				C. D. Wiginton Implications of NSF-Active and NSF-Inert in Nephrogenic Systemic Fibrosis Am. J. Roentgenol., December 1, 2008; 191(6): 1864 - 1866. [Full Text] [PDF]

				J Kay Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction Ann Rheum Dis, December 1, 2008; 67(Suppl_3): iii66 - iii69. [Abstract] [Full Text] [PDF]

				K. Juluru, J. Vogel-Claussen, K. J. Macura, I. R. Kamel, A. Steever, and D. A. Bluemke MR Imaging in Patients at Risk for Developing Nephrogenic Systemic Fibrosis: Protocols, Practices, and Imaging Techniques to Maximize Patient Safety RadioGraphics, November 19, 2008; (2008) 291085072. [Abstract] [Full Text]

				R. Agarwal, S. M. Brunelli, K. Williams, M. D. Mitchell, H. I. Feldman, and C. A. Umscheid Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis Nephrol. Dial. Transplant., October 24, 2008; (2008) gfn593v1. [Abstract] [Full Text] [PDF]

				R. A. Halvorsen Which Study When? Iodinated Contrast-enhanced CT Versus Gadolinium-enhanced MR Imaging Radiology, October 1, 2008; 249(1): 9 - 15. [Full Text] [PDF]

				P. Marckmann, A. H. Nielsen, and J. J. Sloth Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3280 - 3282. [Abstract] [Full Text] [PDF]

				F. G. Shellock and A. Spinazzi MRI Safety Update 2008: Part 1, MRI Contrast Agents and Nephrogenic Systemic Fibrosis Am. J. Roentgenol., October 1, 2008; 191(4): 1129 - 1139. [Abstract] [Full Text] [PDF]

				P. M. Colletti Nephrogenic Systemic Fibrosis and Gadolinium: A Perfect Storm Am. J. Roentgenol., October 1, 2008; 191(4): 1150 - 1153. [Full Text] [PDF]

				T. Liu, T. H. McCalmont, I. J. Frieden, M. L. Williams, M. K. Connolly, and A. E. Gilliam The Stiff Skin Syndrome: Case Series, Differential Diagnosis of the Stiff Skin Phenotype, and Review of the Literature Arch Dermatol, October 1, 2008; 144(10): 1351 - 1359. [Abstract] [Full Text] [PDF]

				H. Steen, C. Merten, S. Refle, R. Klingenberg, T. Dengler, E. Giannitsis, and H. A. Katus Prevalence of Different Gadolinium Enhancement Patterns in Patients After Heart Transplantation J. Am. Coll. Cardiol., September 30, 2008; 52(14): 1160 - 1167. [Abstract] [Full Text] [PDF]

				M. R. Prince, H. Zhang, M. Morris, J. L. MacGregor, M. E. Grossman, J. Silberzweig, R. L. DeLapaz, H. J. Lee, C. M. Magro, and A. M. Valeri Incidence of Nephrogenic Systemic Fibrosis at Two Large Medical Centers Radiology, September 1, 2008; 248(3): 807 - 816. [Abstract] [Full Text] [PDF]

				M. G. Lansberg, V. N. Thijs, R. Bammer, J.-M. Olivot, M. P. Marks, L. R. Wechsler, S. Kemp, and G. W. Albers The MRA-DWI Mismatch Identifies Patients With Stroke Who Are Likely to Benefit From Reperfusion Stroke, September 1, 2008; 39(9): 2491 - 2496. [Abstract] [Full Text] [PDF]

				M E ABOU EL-GHAR, A A SHOKEIR, H F REFAIE, and T A EL-DIASTY MRI in patients with chronic obstructive uropathy and compromised renal function: a sole method for morphological and functional assessment Br. J. Radiol., August 1, 2008; 81(968): 624 - 629. [Abstract] [Full Text] [PDF]

				N. M. Rofsky Nephrogenic Systemic Fibrosis: Considerations for the Cardiologist J. Am. Coll. Cardiol. Img., July 1, 2008; 1(4): 457 - 459. [Full Text] [PDF]

				J. A. Schroeder, C. Weingart, B. Coras, I. Hausser, S. Reinhold, M. Mack, V. Seybold, T. Vogt, B. Banas, F. Hofstaedter, et al. Ultrastructural Evidence of Dermal Gadolinium Deposits in a Patient with Nephrogenic Systemic Fibrosis and End-Stage Renal Disease Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 968 - 975. [Abstract] [Full Text] [PDF]

				N. M. Rofsky, A. D. Sherry, and R. E. Lenkinski Nephrogenic Systemic Fibrosis: A Chemical Perspective Radiology, June 1, 2008; 247(3): 608 - 612. [Full Text] [PDF]

				Y. Tsushima, A. Takahashi-Taketomi, and K. Endo Nephrogenic Systemic Fibrosis in Japan: Advisability of Keeping the Administered Dose as Low as Possible Radiology, June 1, 2008; 247(3): 915 - 916. [Full Text] [PDF]

				R. F. Reilly Risk for Nephrogenic Systemic Fibrosis with Gadoteridol (ProHance) in Patients Who Are on Long-Term Hemodialysis Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 747 - 751. [Abstract] [Full Text] [PDF]

				M. A. Perazella How Should Nephrologists Approach Gadolinium-based Contrast Imaging in Patients with Kidney Disease? Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 649 - 651. [Full Text] [PDF]

				C. Y. Kim, R. A. Mirza, J. A. Bryant, E. D. Whiting, D. M. Delong, C. E. Spritzer, and E. M. Merkle Central Veins of the Chest: Evaluation with Time-resolved MR Angiography Radiology, May 1, 2008; 247(2): 558 - 566. [Abstract] [Full Text] [PDF]

				C. D. Wiginton, B. Kelly, A. Oto, M. Jesse, P. Aristimuno, R. Ernst, and G. Chaljub Gadolinium-Based Contrast Exposure, Nephrogenic Systemic Fibrosis, and Gadolinium Detection in Tissue Am. J. Roentgenol., April 1, 2008; 190(4): 1060 - 1068. [Abstract] [Full Text] [PDF]

				L. P. Golding and J. M. Provenzale Nephrogenic Systemic Fibrosis: Possible Association with a Predisposing Infection Am. J. Roentgenol., April 1, 2008; 190(4): 1069 - 1075. [Abstract] [Full Text] [PDF]

				S. C. Textor, J. F. Glockner, L. O. Lerman, S. Misra, M. A. McKusick, S. J. Riederer, J. P. Grande, S. I. Gomez, and J. C. Romero The Use of Magnetic Resonance to Evaluate Tissue Oxygenation in Renal Artery Stenosis J. Am. Soc. Nephrol., April 1, 2008; 19(4): 780 - 788. [Abstract] [Full Text] [PDF]

				W. M. Shabana, R. H. Cohan, J. H. Ellis, H. K. Hussain, I. R. Francis, L. D. Su, S. K. Mukherji, and R. D. Swartz Nephrogenic Systemic Fibrosis: A Report of 29 Cases Am. J. Roentgenol., March 1, 2008; 190(3): 736 - 741. [Abstract] [Full Text] [PDF]

				J. Kay, H. Bazari, L. L. Avery, and A. F. Koreishi Case 6-2008 -- A 46-Year-Old Woman with Renal Failure and Stiffness of the Joints and Skin N. Engl. J. Med., February 21, 2008; 358(8): 827 - 838. [Full Text] [PDF]

				N. ISSA, E. D. POGGIO, R. A. FATICA, R. PATEL, P. M. RUGGIERI, and R. J. HEYKA Nephrogenic systemic fibrosis and its association with gadolinium exposure during MRI Cleveland Clinic Journal of Medicine, February 1, 2008; 75(2): 95 - 111. [Abstract] [Full Text] [PDF]

				T. Dickfeld, P. Lei, V. Dilsizian, J. Jeudy, J. Dong, A. Voudouris, R. Peters, M. Saba, R. Shekhar, and S. Shorofsky Integration of Three-Dimensional Scar Maps for Ventricular Tachycardia Ablation With Positron Emission Tomography-Computed Tomography J. Am. Coll. Cardiol. Img., January 1, 2008; 1(1): 73 - 82. [Abstract] [Full Text] [PDF]

				C. U. Herborn, V. M. Runge, D. M. Watkins, J. M. Gendron, and L. G. Naul MR Angiography of the Renal Arteries: Intraindividual Comparison of Double-Dose Contrast Enhancement at 1.5 T with Standard Dose at 3 T Am. J. Roentgenol., January 1, 2008; 190(1): 173 - 177. [Abstract] [Full Text] [PDF]

				J. R. Leyendecker, C. E. Barnes, and R. J. Zagoria MR Urography: Techniques and Clinical Applications RadioGraphics, January 1, 2008; 28(1): 23 - 46. [Abstract] [Full Text] [PDF]

				J. R. Dillman, J. H. Ellis, R. H. Cohan, P. J. Strouse, and S. C. Jan Frequency and Severity of Acute Allergic-Like Reactions to Gadolinium-Containing IV Contrast Media in Children and Adults Am. J. Roentgenol., December 1, 2007; 189(6): 1533 - 1538. [Abstract] [Full Text] [PDF]

				A. Kahana, M. J. Lucarelli, A. M. Grayev, J. J. Van Buren, C. N. Burkat, and L. R. Gentry Noninvasive Dynamic Magnetic Resonance Angiography With Time-Resolved Imaging of Contrast KineticS (TRICKS) in the Evaluation of Orbital Vascular Lesions Arch Ophthalmol, December 1, 2007; 125(12): 1635 - 1642. [Abstract] [Full Text] [PDF]

				P. Marckmann, L. Skov, K. Rossen, J. G. Heaf, and H. S. Thomsen Case-control study of gadodiamide-related nephrogenic systemic fibrosis Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3174 - 3178. [Abstract] [Full Text] [PDF]

				J. L. Nortier and V. del Marmol Nephrogenic systemic fibrosis the need for a multidisciplinary approach Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3097 - 3101. [Full Text] [PDF]

				J. B. Othersen, J. C. Maize Jr., R. F. Woolson, and M. N. Budisavljevic Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3179 - 3185. [Abstract] [Full Text] [PDF]

				M. Remy-Jardin, M. Pistolesi, L. R. Goodman, W. B. Gefter, A. Gottschalk, J. R. Mayo, and H. D. Sostman Management of Suspected Acute Pulmonary Embolism in the Era of CT Angiography: A Statement from the Fleischner Society Radiology, November 1, 2007; 245(2): 315 - 329. [Full Text] [PDF]

				C. Thakral and J. L. Abraham Automated scanning electron microscopy and x-ray microanalysis for in situ quantification of Gadolinium deposits in skin J. Electron Microsc. (Tokyo), October 19, 2007; (2007) dfm020v1. [Abstract] [Full Text] [PDF]

				T. A. Collidge, P. C. Thomson, P. B. Mark, J. P. Traynor, A. G. Jardine, S. T. W. Morris, K. Simpson, and G. H. Roditi Gadolinium-enhanced MR Imaging and Nephrogenic Systemic Fibrosis: Retrospective Study of a Renal Replacement Therapy Cohort Radiology, October 1, 2007; 245(1): 168 - 175. [Abstract] [Full Text] [PDF]

				S. Swaminathan and S. V. Shah New Insights into Nephrogenic Systemic Fibrosis J. Am. Soc. Nephrol., October 1, 2007; 18(10): 2636 - 2643. [Abstract] [Full Text] [PDF]

				R. J. Gibbons, P. A. Araoz, and E. E. Williamson The Year in Cardiac Imaging J. Am. Coll. Cardiol., September 4, 2007; 50(10): 988 - 1003. [Full Text] [PDF]

				G. Saab, A. Abu-Alfa, E. A. Sadowski, and A. Djamali Are Patients with Moderate Renal Failure at Risk for Developing Nephrogenic Systemic Fibrosis? Radiology, September 1, 2007; 244(3): 930 - 932. [Full Text] [PDF]

				A. S Peak and A. Sheller Risk Factors for Developing Gadolinium-Induced Nephrogenic Systemic Fibrosis Ann. Pharmacother., September 1, 2007; 41(9): 1481 - 1485. [Abstract] [Full Text] [PDF]

				H. Richmond, J. Zwerner, Y. Kim, and D. Fiorentino Nephrogenic Systemic Fibrosis: Relationship to Gadolinium and Response to Photopheresis Arch Dermatol, August 1, 2007; 143(8): 1025 - 1030. [Abstract] [Full Text] [PDF]

				P. B. Mark, R. K. Patel, and A. G. Jardine Are we overestimating left ventricular abnormalities in end-stage renal disease? Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1815 - 1819. [Full Text] [PDF]